资源描述：
《康复新液辅助治疗颈淋巴结核的临床效果.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、康复新液辅助治疗颈淋巴结核的临床效果［摘要］目的观察康复新液对颈淋巴结核的辅助治疗效果。方法将2012年6月〜2013年6月江苏省无锡市第五人民医院收治的100例颈淋巴结核患者按随机数字表法分为对照组和治疗组，每组50例。对照组常规应用利福平、异烟耕、毗嗪酰胺、乙胺丁醇进行抗结核治疗，治疗组在对照组的基础上加用康复新液。比较不同时间两组患者的症状缓解率、淋巴结吸收率、术后复发率和不良反应及并发症情况。结果治疗组1个月、3个月和6个月临床症状缓解率为90%、98%和100%,较对照组的58%、68%和86%显著升高，差异有高度统计学意义(P〈0・01)。治疗组1个月、3个月和6个月的淋巴结吸
2、收率分别为64%.86%和94%,高于对照组的32%、60%和84%,差异有统计学意义(P<0.05)o与对照组比较，治疗组患者术后复发率和不良反应及并发症的发生率均降低，差异有统计学意义(P<0.05)o结论康复新液联合常规抗结核药可提高颈部淋巴结核的症状缓解率和淋巴结吸收率，降低复发率和不良反应及并发症的发生率，值得临床推广使用。［关键词］康复新液；辅助治疗；颈淋巴结核；临床效果［中图分类号］R522［文献标识码］A［文章编号］1673-7210(2014)09(a)-0078-04［Abstract］ObjectiveToobserveclinicaleffectofKangfuxi
3、nSolution(KFXS)adjuvanttreatingcervicaltuberculosislymphadenitis(CTL).Methods100CTLpatientswhoweretreatedinthe5thPeople'sHospitalofWuxiCityfromJune2012toJune2013weredividedintocontrolgroupandtreatmentgroupbydigitalrandommethod,with50casesineachgroup.Controlgroupwastreatedwithroutineapplicationofan
4、ti-tuberculosistreatmentwithRifampin,Isoniazid,PyrazinamideandEthambutol.TreatmentgroupusedKFXSonthebasisofthecontrolgroup・Lymphnodessymptomremissionrate,absorptionrate,postoperativerecurrencerateandadversereactionsandcomplicationsincidencewerecompared・ResultsClinicalsymptomreliefrateintreatmentgr
5、oupaftertreatedfor1month,3monthsand6monthswere90%,98%and100%respectively,whichweresignificantlyhigherthan58%,68%and86%inthecontrolgroup.Thedifferenceswerestatisticallysignificant(卩〈0.01)•Lymphnodeabsorptionrateintreatmentgroupaftertreatedfor1month,3monthsand6monthswere64%,86%and94%respectively,whi
6、chwerehigherthan32%,60%and84%incontrolgroup,thedifferenceswerestatisticallysignificant(P<0.05)•Comparedwithcontrolgroup,postoperativerecurrencerateandtheincidenceofadversereactionsandcomplicationsintreatmentgroupwerereduced,thedifferenceswerestatisticallysignificant(P<0.05).ConclusionKFXScombinedr
7、outineariti-tuberculosismedicinecanimprovetheneck1ymphnodeslymphoidtuberculosissymptomremissionrateandabsorptionrate,reducetherecurrencerateandincidenceofadversereactionsandcomplications,whichisworthyofclinicalwi
